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Abstract
RNase P is a ribozyme originally identified for its role in maturation of tRNAs by cleavage of 
precursor tRNAs (pre-tRNAs) at the 5′-end termini. RNase P is a ribonucleoprotein consisting of a 
catalytic RNA molecule and, depending on the organism, one or more cofactor proteins. The site 
of cleavage of a pre-tRNA is identified by its tertiary structure; and any RNA molecule can be 
cleaved by RNase P as long as the RNA forms a duplex that resembles the regional structure in the 
pre-tRNA. When the antisense sequence that forms the duplex with the strand that is subsequently 
cleaved by RNase P is in a separate molecule, it is called an external guide sequence (EGS). These 
fundamental observations are the basis for EGS technology, which consists of inhibiting gene 
expression by utilizing an EGS that elicits RNase P-mediated cleavage of a target mRNA 
molecule. EGS technology has been used to inhibit expression of a wide variety of genes, and may 
help development of novel treatments of diseases, including multidrug resistant bacterial and viral 
infections.
Background
RNase P, a ubiquitous ribozyme present in all living organisms, was originally identified for 
its role in the maturation of the 5′-end termini of tRNAs by a single endonucleolytic 
cleavage of the precursor tRNA (pre-tRNA) (Fig. 1A).1-5 Further functional studies found 
that RNase P of different organisms are required for synthesis of other natural RNA 
molecules, such as the precursors to 4.5S RNA, transfer messenger RNA, some 
multicistronic mRNAs, phage-related RNAs, small non-coding RNA genes, and 
others.4, 6-17
The RNase P holoenzyme is a ribonucleoprotein composed of the RNA molecule 
responsible for its catalytic activity 3 and one or more proteins as cofactors with different 
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functions, which, in some cases, remain unknown.8, 18 Bacterial RNase P usually contains 
one protein, while archaeal and human counterparts include between 5 and 10 proteins.19 
Although structural studies on RNase P holoenzymes are still at an early stage, the structure 
of a bacterial RNase P in complex to mature tRNA has been resolved at high resolution.20
Early applications of external guide sequence technology
The Escherichia coli RNase P consists of the 377-nucleotide catalytic RNA subunit M1 and 
the 119 amino acids cofactor protein C5.21-23 The holoenzyme recognizes the acceptor stem 
(Fig. 1A) and, possibly, the T stem-loop regions in pre-tRNAs, which form a particular 
structure recognized by RNase P.4, 22, 24-26 Experiments designed to determine domains in a 
pre-tRNA molecule without abolishing E. coli RNase P activity demonstrated that most of 
the pre-tRNA molecule could be removed; these experiments also showed that any 
bimolecular complex with the appropriate structure could also be a substrate for RNase P 
(Fig. 1B).24, 27-29 Importantly, the (antisense) complementary oligoribonucleotide was the 
only requirement to guide bacterial RNase P to cleave the target RNA molecule; when the 
antisense sequence that forms the duplex with the RNA is in a separate molecule, it is called 
an external guide sequence (EGS) (Fig. 1B).26-28 This fundamental finding led to the 
development of EGS technology, which consists of inhibiting gene expression by utilizing 
an EGS that elicits RNase P-mediated cleavage of a target RNA molecule.25, 26, 30-32
The general path to selection of EGSs consists of first identifying the regions in the target 
RNA molecule that are accessible for interaction with an antisense oligonucleotide (or 
oligonucleotide analog). This can be achieved by different methods, such as RNase H 
mapping,33, 34 cleavage assay by random EGSs,35 dimethyl sulfate in vivo mapping, 36-38 or 
digestion with specific enzymes.39-41 The results obtained can be further refined using 
computer prediction of the secondary structure of the RNA molecule using software such as 
mfold.42 EGSs are designed to target regions that are identified by one or more methods and 
then evaluated for their ability to elicit RNase P-mediated cleavage of the target RNA in 
vitro or in vivo (whole cells or animal models). EGS technology has been used to inhibit the 
expression of a wide range of genes.43-46 Early applications of the technology were in 
animal cell gene expression,47-51 plant cells,52, 53 parasites,54 as well as Saccharomyces 
cerevisiae.55
In this review, we briefly summarize illustrative examples of the utilization of EGS 
technology in development of antibacterial and antiviral compounds. A summary of 
applications of EGS technology to infectious agents is shown in Table 1.
First EGS application in E. coli
The first example of EGS-mediated gene-regulation was published by Guerrier-Takada et 
al.56 EGSs were utilized to reduce expression of β-galactosidase and alkaline phosphatase in 
E. coli. The EGSs used in E. coli and other bacterial systems usually include a 13–16 
nucleotide antisense molecule complementary to the target region that also has the addition 
of an RCCA sequence at the 3′ end, which facilitates interaction with RNase P (Fig. 
1B). 7, 57 Because RNA molecules are extremely unstable and do not penetrate E. coli cells 
readily, an appropriate recombinant plasmid that expresses the EGS was used. The release of 
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the EGS sequence was achieved by designing a DNA insert consisting of a T7 promoter, the 
EGS sequence, a core hammerhead sequence, and a T7 terminator (T7p–EGS–HH–T7t). 
After induction and expression of the RNA, the core hammerhead ribozyme promotes self-
cleavage and releases the EGS into the cytosol.58 An RNase P temperature-sensitive E. coli 
mutant was transformed with recombinant plasmids that expressed either specific EGSs 
antisense to regions in target mRNAs or non-complementary sequences as negative controls. 
Inhibition of gene expression was elicited by the specific EGSs, which did not occur when 
the cells were cultured at the restrictive temperature, indicating that RNase P mediated the 
cleavage of the mRNA. Similar experiments were then carried out in which the same 
strategy was applied except that the EGSs were complementary to blaTEM (the gene that 
encodes β-lactamase) and cat (the gene that encodes chloramphenicol acetyl transferase). In 
these cases, there was significant inhibition of expression of the respective gene products 
and thus resistance to ampicillin (in the case of blaTEM-directed EGS) and chloramphenicol 
(in the case of cat-directed EGS).58
EGS technology applied to human viruses
Yuan et al. 59 first showed that human RNase P can cleave an RNA substrate in the presence 
of an appropriate EGS that forms a bimolecular complex. However, the characteristics of the 
human EGSs were different from those designed for use with E. coli RNase P.32, 59 These 
studies showed that an EGS consisting of the sequence adjacent to a 5-or 6-base pair helix, 
connected through a bulge with a second 7–8 base pair helix, efficiently elicits cleavage of 
the target RNA by human RNase P (Fig. 2A).60, 61 It was later shown that exogenous 
administration of a 2′-O-methyl modified oligonucleotide analog EGS in complex with the 
transfecting reagent Lipofectin also induced cleavage of a target mRNA by RNase P in cells 
in culture.43
Anti-HIV EGS
Replication of human immunodeficiency virus type 1 (HIV-1) was suppressed by designing 
EGSs targeting tat mRNA and the U5 region of the long terminal repeat (LTR).62 The Tat 
protein is a positive regulator of expression of HIV-1 genes at the level of transcriptional 
elongation.63 The LTR contains the viral promoter, which is responsible for viral gene 
expression in eukaryotic cells, and, is present in both early and late viral gene products.64, 65 
Expression of EGSs in tissue culture cells (COS cells, a fibroblast-like cell line from 
monkey kidney tissue) was carried out by transfecting the cells with plasmids in which the 
EGS sequences were cloned into the mammalian expression vector pSV2neo, along with 
either the human tRNAmet or human U6 snRNA promoter upstream and the pol III 
termination downstream of the EGS sequences. Although EGSs specific for several HIV-1 
genes efficiently inhibited replication of the virus, the highest inhibitory effect was observed 
with the EGS that targeted the HIV-1 tat gene. 62 Furthermore, no significant differences 
were found when the EGSs were expressed using either of the two promoters.
Anti-HBV EGS
Another study focused on inhibition of the hepatitis B virus (HBV). 66, 67 The HBV pre-
genomic RNA (pgRNA), which is the template for DNA genome synthesis, and the mRNAs 
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for the viral polymerase and core protein were mapped using the dimethyl sulphate 
method37 to identify regions accessible for interaction with EGSs. A region that when 
digested by RNase P would affect expression of essential viral proteins, as well as the level 
of viral genomic DNA, was chosen as the target. The bimolecular complex of EGS and 
target mRNA is shown in Fig. 2B. In vitro assays showed that the pgRNA substrate was 
efficiently cleaved when incubated in the presence of human RNase P and the EGS. The 
EGS sequence was then cloned into an expression vector under the control of the U6 
promoter, along with the gene for green fluorescence protein (GFP). The recombinant 
plasmid was introduced into the attenuated Salmonella strain SL301, developed specifically 
for gene delivery.68 The transfected strain was then used to infect human hepatoma HepG2 
cells; 24 hours after infection >70% of cells expressed GFP and the EGS at high levels.66 
Experiments to determine inhibition of replication of HBV in infected cells in culture were 
performed by infecting hepatoma cells with HBV followed by delivery of the EGS using the 
Salmonella delivery strain. After treatment, the hepatoma cells were sorted based on 
expression of the green fluorescent protein (i.e., the cells that acquired and expressed the 
EGS-containing plasmid); these cells showed 92% and 93% reduction of the HBV 3.5 kb 
and 2.4/2.1 kb transcripts, respectively. Further experiments were carried out using an 
animal model consisting of mice injected with an HBV genomic DNA plasmid that reaches 
liver tissue and is expressed, leading to secretion of hepatitis B-related antigens.69 When the 
transfected mice were treated by oral inoculation of Salmonella expressing the EGS, a 
reduction of ~200,000-fold in viral DNA in the liver and serum was observed.66 This work 
was followed by an analysis of different EGS variants to maximize their ability to elicit 
RNase P-mediated cleavage of the HBV target.67
Anti-CMV EGS
Human cytomegalovirus, CMV, is a cause of serious disease for immunocompromised 
patients. Compounding this problem, numerous strains are becoming resistant to available 
treatments. CMV was the target for the first antisense therapeutic agent, fomivirsen, which 
was approved by the FDA in 1998 for intravitreal injectable treatment of CMV retinitis.70 
Fomivirsen is a 21-base phosphorothioate oligonucleotide analog that functions by blocking 
translation of the viral immediate-early gene mRNA.71
The application of EGS technology may provide new therapeutic alternatives to prevent 
replication of CMV. For example, Jiang et al. mapped the mRNA encoding the protease 
(mPR) of murine CMV, whose infection of mice is similar to that of human CMV infection 
in humans, and selected a location 160 nucleotides downstream from the mPR translational 
initiation codon to design the EGS.36 Two identical EGSs were designed, with the exception 
of three highly conserved nucleotides within the T-loop that are important for interaction 
with RNase P (Fig. 2C and D). In vitro assays of RNase P cleavage showed that in spite of 
both EGSs having the same binding activity with the target mRNA, only the EGS with 
nucleotides corresponding to the tRNASer in the T loop was active. Thus, substitution of the 
three nucleotides rendered the mutated EGS inactive, proving the crucial role of these 
nucleotides in the action of RNase P.36
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The active EGS was cloned into an expression vector that was introduced into a Salmonella 
strain for gene delivery in vivo; murine CMV–infected mice were treated orally with 
Salmonella carrying recombinant plasmids expressing either the EGS to be tested or EGSs 
controls. The infected mice treated with the active, but not control, EGS showed reduced 
levels of mPR and viral titers, and increased survival.36
In other experiments, the mRNA necessary for CMV capsid scaffolding protein expression 
and assembly, both essential for capsid formation, was targeted.72 An EGS lacking the 
anticodon loop was more effective in reducing expression of the proteins and viral growth in 
human CMV–infected cells in culture compared to an EGS that formed a tRNA-like 
structure when in complex with the target mRNA. The levels of reduction of protein 
expression and viral growth by the former EGS were 98% and 7000-fold, respectively, in 
contrast to 75% and 250-fold, respectively, by EGS that formed a tRNA-like structure.72
Both human and murine CMVs were also used to assess the efficiency of M1 guide 
sequence (M1GS) molecules (RNA molecules consisting of the EGS sequence linked to the 
3′ end of the M1 RNA).73, 74 The overlapping region of the murine CMV mRNA that codes 
for the M80.5 protein and the viral protease, both essential for viral replication, was used as 
the target for an M1GS that mediated mRNA cleavage. The DNA sequences of M1GSs were 
cloned in a plasmid under the control of the U6 promoter and introduced in a Salmonella 
strain for gene delivery in vivo.73 CMV-infected macrophages and murine CMV–infected 
mice were treated with the Salmonella transformants. Macrophages treated with one of the 
M1GSs showed a reduction in the synthesis of both M80.5 and protease of about 80–85%, 
and a 2,500-fold reduction in viral growth, compared to the controls. Oral treatment of 
infected mice resulted in improved survival, as well as reduced viral titers.73
In yet another experiment, a M1GS that targeted the human CMV immediate-early protein 2 
mRNA, using the wild-type sequence of the ribozyme, resulted in a 75% reduction in the 
expression of the protein and a100-fold reduction in viral production in infected human cells 
in culture. However, when a variant that included two point mutations in the ribozyme 
component of the M1GS (A94G and G194C), known to confer higher catalytic activity to 
the ribozyme in vitro,75 was used, significantly more activity was observed, with reductions 
of protein expression by 98% and virus production by 3500-fold.74
Anti-HSV-1 EGS
The thymidine kinase mRNA from the herpex simplex virus 1 (HSV-1) has been targeted by 
EGS for inhibition of HSV-1 viral gene expression.37, 76 The fragment around the 
translation initiation site of the mRNA was mapped in vivo using the dimethyl sulfate 
technique. The mRNA region selected to target with an EGS would result in cleavage at 
nucleotide 29 downstream of the translation initiation codon. The EGS designed was 71-
nucleotides and formed a tRNA-like structure in complex with the target HSV-1 mRNA. 
Two additional EGSs were designed and tested, one with a C->G substitution at the highly 
conserved T-loop sequence and the other with a deletion of a portion equivalent to the 
anticodon domain of the EGS. The three EGSs were assayed to determine their ability to 
elicit cleavage of the thymidine kinase mRNA by RNase P. The EGS lacking the anticodon 
domain cleaved most efficiently, while the EGS with the C->G substitution showed very 
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low activity. However, the binding affinity to the thymidine kinase mRNA substrate was 
similar for both EGSs, indicating that the nucleotide change interfered with formation of the 
adequate structure for the EGS–mRNA complex to be recognized by RNase P.32 In 
additional experiments, the DNAs coding for the EGSs were cloned under the control of the 
U6 promoter and the recombinant plasmids were transfected into human cells in culture that 
were then infected with HSV-1. A significant inhibition of expression of viral thymidine 
kinase was observed with the EGS that were shown to be active in the earlier assays.32 
Following these results, a pool of EGSs generated with random mutations was put through 
an in vitro selection procedure to identify a highly active EGS that reduced expression of 
thymidine kinase in HSV-1-infected cells by 95%.37
Anti-Influenza virus EGSs
Production of influenza virus from infected cells in tissue culture has been inhibited by 
addition of two EGSs that target two flu virus mRNA molecules coding for the polymerase 
subunit 2 (PB2) and the nucleoprotein NP.77 Both proteins are essential for replication and 
production of viral particles.78 Target regions were selected by mapping RNase T1 digestion 
sites within mRNAs. EGSs were designed and cloned into the LSXN cloning vector under 
the control of the U6 promoter. The recombinant clones were introduced into mouse cells in 
culture, which were then infected with flu virus at a multiplicity of infection (MOI) high 
enough to ensure infection of all the cells. Inhibition of protein expression and production of 
viral particles was observed in those cases where the cells expressed the EGSs from 
recombinant clones. However, as anticipated, not all EGSs showed the same level of 
inhibition. The strongest inhibitions, ~90% (MOI = 3) and 50% (MOI = 10), were achieved 
with an EGS targeting the PB2 mRNA. Introduction of another recombinant clone 
consisting of the vector RVY with an EGS that targets the NP mRNA resulted in cells from 
which particle production was inhibited 90–100% at a MOI = 10.77 To demonstrate that 
RNase P mediated cleavage, an EGS was designed with a defective T-loop that prevented 
RNase P activity;77 all experiments using this control EGS showed no inhibition of virus 
replication.
EGS technology applied to bacterial pathogens
Following the pioneering work by Guerrier-Takada et al. 56, 58 described above, several 
groups attempted to overcome antibiotic resistance or target essential genes in a variety of 
bacterial pathogens (Table 1).
E. coli: GyrA and the C5 subunit of RNase P
McKinney et al. successfully designed EGSs that targeted mRNAs coding for GyrA and the 
C protein (C5) component of RNase P.79 Two EGSs targeting different regions of either the 
gyrA or the C5 mRNA were cloned in a single DNA sequence with the orientation T7p–
EGS1–HH1–HH2–EGS2–HH3–T7t. E. coli cells were transformed with the recombinant 
clones and upon induction a decrease in viability of about 10-fold was observed targeting 
either the gyrA or the C5 mRNA.79 A recombinant clone that included all four EGSs, i.e., 
two specific for gyrA mRNA and two specific for C5 mRNA, was also tested. The results 
showed additive, but not synergistic, effects. An analysis of the efficiency of the EGSs 
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targeting gyrA demonstrated that up to three mismatches did not impair the inhibitory effect 
of the EGS.79
E. coli: aac(6′)-Ib and ftsZ
The aminoglycoside 6′-N-acetyltransferase type Ib (AAC(6′)-Ib) is a clinically relevant 
enzyme that confers resistance to several aminoglycosides, including amikacin.80-82 The 
gene aac(6′)-Ib has been found in numerous plasmids, transposons, and integrons in Gram-
negative bacteria.83, 84
Available regions for interaction with EGSs were determined by a combination of a 
computer generated secondary structure and RNase H mapping (Fig. 3A).33, 34 A battery of 
EGSs targeting the selected regions was then tested in vitro to assess efficiency in eliciting 
RNase P-mediated cleavage (Fig. 3B).85 Those with the higher efficiency were cloned into a 
vector similar to that used by Guerrier-Takada et al. 58 (i.e., T7p–EGS–HH–T7t) and 
transferred to E. coli carrying aac(6′)-Ib. Cells with one of the EGSs, EGSC3, showed 
growth inhibition upon addition of amikacin (Fig. 3C).85 It is noteworthy that the target 
region (region C, Fig. 3B and C) is not entirely single-stranded in its predicted structure: 
four nucleotides are predicted to be in double-stranded form. Nevertheless, it was identified 
as region accessible for interaction with an antisense sequence by RNase H mapping (Fig. 
3B and C). Possible explanations are that either the predicted structure may not reflect the 
precise structure of the mRNA or the structural complexity of the region permits breathing 
at the short double-stranded stems, allowing interaction with the EGS.34, 86
A strategy similar was used to interfere with normal expression of the ftsZ gene. FtsZ is 
essential for cell division and together with FtsA and ZipA participate in the first event of 
construction of the divisome, the formation of the proto-ring, which continues with the 
assembly of other proteins and protein complexes. FtsZ functions as a scaffold for the 
divisome and generates the constrictive force to initiate cell division.87-90
The ftsZ mRNA was mapped and EGS targeting regions accessible for interaction with 
antisense sequences were tested in vitro to determine the best candidates to elicit cleavage 
by RNase P (Fig. 3D).91 These assays led to selection of a few EGSs that were promising 
with respect to interfering with expression of ftsZ and disrupting cell division. The selected 
EGSs were cloned as part of a DNA fragment with the structure T7p–EGS–HH–T7t, and the 
recombinant clones were introduced in E. coli. Upon induction of the T7 promoter, cells 
expressing specific EGSs showed filamentation, indicating that cell division had been 
disrupted (see Fig. 3E and F).91
Salmonella enterica serovar Typhimurium
McKinney et al. designed EGSs that target the invC and invB genes found in the Salmonella 
enterica serovar Typhimurium.39 The invC and invB genes code for an ATPase required for 
host cell invasion and a type III secretion chaperone, respectively.92, 93 Mapping of mRNA 
was carried out by RNase T1 digestion and four EGSs, three of them targeting invC, were 
designed on the basis of the mapping results. The EGSs were capable of inducing digestion 
of the target mRNAs in vitro and were cloned into high and low copy number vectors to be 
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expressed within a Salmonella strain. Expression of all four EGSs resulted in a decrease in 
invC mRNA, consistent with the existence of a dicistronic mRNA. Assays to determine the 
effect on InvC-dependent type III secretion expressing two EGSs, both targeting invB or 
invC or one targeting invB and the other targeting invC, showed a reduction in secretion of 
the protein SipB and the levels of reduction were dependent on the copy number of the 
recombinant plasmids used. Expression of two EGSs, one targeting invC and the other invB, 
also resulted in inhibition of expression of InvC.
Finally, in cell invasion assays, Salmonella expressing EGSs targeting invB or invC from a 
high copy number plasmid exhibit about 90% reduction in invasion with respect to the 
controls.39 The authors proposed that both invC and invB are encoded in the same mRNA 
and the 3′ nucleotide of the final codon of invB is the 5′ nucleotide of the initial codon of 
invC. Then, since all four EGSs resulted in inhibition of expression of invC, it is possible 
that the mRNA is destabilized or functionally disrupted after cleavage at the invB location. 
This result suggests the non-surprising possibility that EGS targeting one region of an 
mRNA may have deleterious effects on the rest of the molecule.39
Yersinia pestis, Francisella tularensis, and Brucella melitensis
Ko et al. 41 applied EGS technology to inactivate the Yersinia pestis virulence genes yscN 
and yscS, which are part of a group of more than 20 genes that form a Type III secretion 
system, which is induced upon entry of Y. pestis into the mammalian host and when the 
bacterium makes contact with the mammalian cell it mediates injection of the effectors, 
known as Yop proteins, through the cell membrane. Once inside the eukaryotic cell, the 
effectors inhibit bacterial phagocytosis and suppress the production of pro-inflammatory 
cytokines.94
Messenger RNAs for both yscN and yscS were mapped and EGSs were designed that proved 
active in in vitro assays. To test their ability to elicit RNase P-mediated cleavage of the 
mRNAs in vivo using E. coli as host, the EGSs and the target mRNA were cloned into 
expression vectors.41 The results showed that the most effective EGSs reduced the target 
mRNAs to 37–40% compared to the control condition of expressing the mRNA in the 
absence of an EGS.
A similar strategy was used to design EGSs that inhibit expression of the global virulence 
regulator MglB from Francisella tularensis,95 an intracellular pathogen that causes 
tularemia.96 The mglB mRNA was mapped and EGSs were designed and tested in vitro and 
then recombinant plasmids equivalent to those described for the Y. pestis system were 
constructed and assayed. Two EGSs alone or expressed tethered to M1 RNA reduced 
mRNA levels significantly.
Likewise, EGSs that reduce levels of the Brucella melitensis vjbB gene, which codes for the 
virulence regulator VjbB, have been identified following the same methodologies.35, 95
Modifications of EGSs to aid stability
While the recombinant plasmid based expression of EGSs from within the cells cytosol is 
appropriate as a general strategy to demonstrate proof of concept, it is not viable for 
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therapeutic purposes because the EGSs added exogenously must penetrate the cells to exert 
their action. Furthermore, because oligoribonucleotides are rapidly degraded by nucleases, 
successful development of EGS technology depends on finding nuclease-resistant analogs 
that induce RNase P-mediated degradation of the target mRNA.
In the case of aac(6′)-Ib, locked nucleic acid (LNA)/DNA co-oligomers in the appropriate 
configuration efficiently elicited RNase P-mediated cleavage of the mRNA in vitro.97 
Interestingly, unlike most oligonucleotides and oligonucleotide analogs that are not 
internalized, LNA/DNA co-oligomers were able to penetrate E. coli cells, but with very low 
efficiency.98 Therefore, their ability to interfere with amikacin resistance was assessed using 
the hyperpermeable E. coli AS19 strain.99 Administration of an LNA/DNA co-oligomer at 
50 nM to E. coli AS19 cells harboring the aac(6′)-Ib gene significantly reduced the levels of 
resistance to amikacin.97
In a different study, phosphorodiamidate morpholino oligonucleotide EGSs conjugated to 
permeabilizer peptide (PPMO) efficiently inhibited expression of Gram-negative and Gram-
positive genes.100, 101 Interestingly, these experiments showed that a mix of the PPMO that 
specifically targets an mRNA and permeabilizer peptide that remained in the mix as 
unreacted substrate during the conjugation reaction act as a powerful antibiotic.102, 103 The 
permeabilizer peptide possessed an unspecific antibacterial activity, while the PPMO 
functioned as a specific agent targeting a unique mRNA.102
PPMOs were also successfully used in experimental treatment of Staphylococcus aureus 
wound infection.104 A PPMO EGS was designed to target the gyrA mRNA and it proved 
effective in interfering with growth of S. aureus in liquid cultures.103 Furthermore, the 
PPMO was combined with a gel to assess its activity as a topical treatment in a mouse model 
of S. aureus infected skin wounds.105 Mice that were treated with the PPMO-containing gel 
showed faster re-epithelization and healing when compared to the controls.104
Concluding remarks
Infectious diseases are one of the leading causes of loss of human life. The continuous 
emergence of new threats and development of resistance to available treatments requires 
novel approaches to find means to extend the useful life of existing therapies and design new 
ones. EGS technology is a relatively new strategy that shows promise in the struggle to 
design novel therapeutic agents. Future research could focus on targeting conserved genes 
present in viruses or multidrug resistant bacterial pathogens such as efflux pumps, the 
replication machinery or selected virulence factors genes. Heretofore, success has been 
demonstrated in a variety of cell processes. Although this bodes well for the future of EGS 
technology, many challenges still lie ahead before EGS-based therapeutics can be 
introduced in the clinics. Successful delivery of the drugs to the appropriate targets, 
achieving high levels of inhibition of gene expression, and low toxicity to the host are just 
some them. The various strategies and approaches to design efficient EGSs and delivery 
vehicles described in this review attempt to overcome them.
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Fig. 1. 
Cleavage of a pre-tRNA and an mRNA. (A) The arrow shows the site of action of RNase P 
on a pre-tRNA. The clear segment is the acceptor stem. (B) Complex between a target 
mRNA and an EGS that can be recognized as substrate by bacterial RNase P. In this 
example, the ATG sequence has been added to represent the possibility of using an mRNA 
as target. The RCCA sequence mimics the 3′-end of the pre-tRNA and facilitates interaction 
with RNase P. Redrawn from Ref. 4.
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Fig. 2. 
Schematic representation of complexes target RNA:EGS. (A) Bimolecular substrate of 
human RNase P. (B–D) Complexes between the hepatitis B pgRNA sequence (red),B, the 
mPR mRNA (red), C and D, and the respective EGSs (blue). The nucleotides substituted 
between EGSmPR1 and EGSmPR2 are circled. The arrow indicates the point of action of 
human RNase P. Redrawn from Refs. 36, 60, 66.
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Fig. 3. 
RNase P-mediated inhibition of amikacin resistance and cell division by endogeneously 
produced EGSs. (A) Secondary structure of the aac(6′)-Ib mRNA as determined by utilizing 
a combination of mfold software42 and RNase H mapping.33 Reproduced from Ref. 34. (B) 
Cleavage reactions carried out in vitro in the presence of several EGSs targeting different 
regions in the mRNA (A2, B6, C3, D1, and E1). Controls lacked EGS or RNase P, or 
included EGSs targeting a different gene (bla) or carrying the sense nucleotide sequence. 
The RNase P components, M1 RNA and C5 protein, were incubated with end-labeled 
aac(6′)-Ib mRNA and the EGSs. The products were analyzed on 6% denaturing 
polyacrylamide gel electrophoresis. Reproduced from Ref. 85. (C) E. coli BL21(DE3) 
harboring the aac(6′)-Ib gene and recombinant plasmids coding for the EGSs indicated in 
the figure were cultured in the presence of 15 μg of amikacin/ml. Growth was monitored by 
measuring the OD600. The EGSs were: EGSC3, targets the sequence shown in red in the 
inset, EGSAP, targets the alkaline phosphatase gene, and EGSC3s has the sense sequence. 
The inset shows the region targeted by EGSC3 (nucleotides in red). Reproduced from Ref. 
34. (D) Secondary structure of the ftsZ mRNA as determined by mfold software. The boxed 
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region is shown in detail and the sequence in red is the target of the most efficient EGS 
tested. Redrawn from Ref. 91. (E and F) E. coli BL21(DE3)(pLysS) harboring recombinant 
plasmids coding for the EGS that targets ftsZ, E, or the complementary sequence, F, under 
the control of the T7 promoter were induced by addition of isopropyl-β-D-
thiogalactopyranoside, incubated for 60 minutes at 37 °C and examined by microscopy.
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Table 1
EGS technology applied to infectious diseases
Organism Diseasea Target Chemical nature ofEGS
Proof-of-concept
system
Reference
HIV-1 AIDS tat and LTR RNAb COS cells (mouse) 62
Hepatitis B virus Hepatitis pgRNA, S mRNA, 
pre-S/L mRNA RNA
b,c HepG2 and
HepG2.2.15 cells
(human)b
66, 67
Micec
Murine cytomegalovirus Cytomegalovirus
infection
mPR RNAc J774c, human U373MGb 
cells (human)
36, 72, 74
Micec
Herpes simplex virus
1
Herpes thymidine kinase RNAb 143 tk- cells
(human)b
37, 76
Influenza virus Flu polymerase subunit 2
(PB2), nucleoprotein
(NP)
RNAb C127 cells
(mouse)b
77
E. coli NA phoA, lacZ, RNAb E. coli cells in
culture
56
E. coli NA bla, cat RNAb E. coli cells in
culture
58
E. coli NA gyrA, rnpA RNAb E. coli cells in
culture
79
E. coli NA aac(6′)-Ib RNAb, LNA/DNAd E. coli cells in
culture
85, 97
E. coli NA ftsZ RNAb E. coli cells in
culture
91
S. aureus Wound infection gyrA PPMOe S. aureus cells in
culture
104
Murine
cutaneous wound
model
E. coli NA (tularemia) F. tularensis mlgB RNAf E. coli cellsharboring
heterologous
gene in culture
95
S. enterica Salmonella infection invB, invC RNAb S. entericainvasion of Henle-
407 cells (human)
39
E. coli NA (plague) Y. pestis yscN and 
yscS RNA
f E. coli cells
harboring
heterologous
gene in culture
41
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Organism Diseasea Target Chemical nature ofEGS
Proof-of-concept
system
Reference
E. coli NA (brucellosis) B. melitensis vjbB RNAf In vitro cleavage
of mRNA
35
E. coli
B. subtilis
E. faecalis
NA gyrA PPMOe Bacterial cells in
culture
100
P. aeruginosa
S. aureus
NA gyrA PPMOe In vitro cleavage
of mRNA
100
E. coli
B. subtilis
E. faecalis
NA rnpA PPMOe In vitro cleavage
of mRNA
100
E. coli NA cat PPMOe Bacterial cells in
culture
100
Plasmodium
falciparum
Malaria gyrA PPMOe P. falciparum
cells in culture
54
a
In those cases where the inhibition of expression of the gene(s) in question was done in E. coli harboring the gene(s), the disease caused by the 
bacterium providing the gene(s) is indicated in parenthesis. NA, not applicable.
b
Recombinant clones coding for EGSs were introduced in cells (prokaryotic or eukaryotic) as described in the text.
c
The EGS was in a recombinant clone harbored by a Salmonella strain constructed for delivery.
d
LNA/DNA, oligomer composed of LNA and deoxynucleotide residues.
e
PPMO, phosphorodiamidate morpholino oligonucleotide EGS conjugated to permeabilizer peptide.
fA recombinant plasmid expressing both the EGS and the target gene was introduced in E. coli to test the EGS activity on gene expression.
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